These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 19430883)

  • 1. Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.
    Plotkin SR; Halpin C; Blakeley JO; Slattery WH; Welling DB; Chang SM; Loeffler JS; Harris GJ; Sorensen AG; McKenna MJ; Barker FG
    J Neurooncol; 2009 May; 93(1):61-77. PubMed ID: 19430883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
    Plotkin SR; Halpin C; McKenna MJ; Loeffler JS; Batchelor TT; Barker FG
    Otol Neurotol; 2010 Sep; 31(7):1135-43. PubMed ID: 20736812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.
    Karajannis MA; Legault G; Hagiwara M; Ballas MS; Brown K; Nusbaum AO; Hochman T; Goldberg JD; Koch KM; Golfinos JG; Roland JT; Allen JC
    Neuro Oncol; 2012 Sep; 14(9):1163-70. PubMed ID: 22844108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma.
    Plotkin SR; Allen J; Dhall G; Campian JL; Clapp DW; Fisher MJ; Jain RK; Tonsgard J; Ullrich NJ; Thomas C; Edwards LJ; Korf B; Packer R; Karajannis MA; Blakeley JO
    Neuro Oncol; 2023 Aug; 25(8):1498-1506. PubMed ID: 37010875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.
    Mautner VF; Nguyen R; Kutta H; Fuensterer C; Bokemeyer C; Hagel C; Friedrich RE; Panse J
    Neuro Oncol; 2010 Jan; 12(1):14-8. PubMed ID: 20150363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.
    Karajannis MA; Legault G; Hagiwara M; Giancotti FG; Filatov A; Derman A; Hochman T; Goldberg JD; Vega E; Wisoff JH; Golfinos JG; Merkelson A; Roland JT; Allen JC
    Neuro Oncol; 2014 Jan; 16(2):292-7. PubMed ID: 24311643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
    Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
    Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Audiologic Natural History of Small Volume Cochleovestibular Schwannomas in Neurofibromatosis Type 2.
    deTorres AT; Brewer CC; Zalewski CK; King KA; Walker R; Scott GC; Asthagiri AR; Chittiboina P; Kim HJ
    Otol Neurotol; 2018 Mar; 39(3):357-364. PubMed ID: 29342057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric cerebellopontine angle and internal auditory canal tumors: clinical article.
    Holman MA; Schmitt WR; Carlson ML; Driscoll CL; Beatty CW; Link MJ
    J Neurosurg Pediatr; 2013 Oct; 12(4):317-24. PubMed ID: 23909617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.
    Nghiemphu PL; Vitte J; Dombi E; Nguyen T; Wagle N; Ishiyama A; Sepahdari AR; Cachia D; Widemann BC; Brackmann DE; Doherty JK; Kalamarides M; Giovannini M
    J Neurooncol; 2024 Apr; 167(2):339-348. PubMed ID: 38372904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
    Blakeley JO; Ye X; Duda DG; Halpin CF; Bergner AL; Muzikansky A; Merker VL; Gerstner ER; Fayad LM; Ahlawat S; Jacobs MA; Jain RK; Zalewski C; Dombi E; Widemann BC; Plotkin SR
    J Clin Oncol; 2016 May; 34(14):1669-75. PubMed ID: 26976425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
    Plotkin SR; Duda DG; Muzikansky A; Allen J; Blakeley J; Rosser T; Campian JL; Clapp DW; Fisher MJ; Tonsgard J; Ullrich N; Thomas C; Cutter G; Korf B; Packer R; Karajannis MA
    J Clin Oncol; 2019 Dec; 37(35):3446-3454. PubMed ID: 31626572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium.
    Fisher LM; Doherty JK; Lev MH; Slattery WH
    Otol Neurotol; 2009 Sep; 30(6):835-41. PubMed ID: 19704365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes.
    Lu VM; Ravindran K; Graffeo CS; Perry A; Van Gompel JJ; Daniels DJ; Link MJ
    J Neurooncol; 2019 Sep; 144(2):239-248. PubMed ID: 31254266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2.
    Osorio DS; Hu J; Mitchell C; Allen JC; Stanek J; Hagiwara M; Karajannis MA
    J Neurooncol; 2018 Sep; 139(3):749-755. PubMed ID: 29948766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab for Hearing Preservation in Neurofibromatosis Type 2: Emphasis on Patient-Reported Outcomes and Toxicities.
    Sverak P; Adams ME; Haines SJ; Levine SC; Nascene D; Sommer K; Dusenbery K; Huang TC; Moertel C
    Otolaryngol Head Neck Surg; 2019 Mar; 160(3):526-532. PubMed ID: 30373466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2.
    Huang V; Bergner AL; Halpin C; Merker VL; Sheridan MR; Widemann BC; Blakeley JO; Plotkin SR
    Otol Neurotol; 2018 Jun; 39(5):632-638. PubMed ID: 29649040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofibromatosis 2 invasion of the internal auditory canal wall: clinical significance.
    Doherty J; Go JL; Linthicum FH
    Otol Neurotol; 2014 Oct; 35(9):1662-8. PubMed ID: 25118583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2.
    Farschtschi S; Kollmann P; Dalchow C; Stein A; Mautner VF
    Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3857-60. PubMed ID: 25794543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hearing and facial function outcomes for neurofibromatosis 2 clinical trials.
    Plotkin SR; Ardern-Holmes SL; Barker FG; Blakeley JO; Evans DG; Ferner RE; Hadlock TA; Halpin C;
    Neurology; 2013 Nov; 81(21 Suppl 1):S25-32. PubMed ID: 24249803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.